Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity.
BACKGROUND
Filaggrin, coded by FLG, is the main source of several major components of natural moisturizing factor (NMF) in the stratum corneum (SC), including pyrrolidone carboxylic acid (PCA) and urocanic acid (UCA). Loss-offunction mutations in FLG lead to reduced levels of filaggrin degradation products in the SC. It has recently been suggested that expression of filaggrin may additionally be influenced by the atopic inflammatory response. In this study, we investigated the levels of several breakdown products of filaggrin in the SC in healthy controls (CTRL) and patients with atopic dermatitis (AD) in relation to FLG null allele status. We examined the relationship between NMF (defined here as the sum of PCA and UCA) and AD severity.


METHODS
The SC levels of filaggrin degradation products including PCA, UCA, histidine (HIS) and tyrosine were determined in 24 CTRL and 96 patients with moderate-to-severe AD. All subjects were screened for 11 FLG mutations relevant for the study population.


RESULTS
The levels of PCA, UCA and HIS correlated with FLG genotype. Furthermore, these levels were higher in the CTRL when compared to AD patients with no FLG mutations. Multiple regression analysis showed that NMF levels were independently associated with FLG genotype and severity of disease.


CONCLUSIONS
Decreased NMF is a global feature of moderate-to-severe AD; within AD, FLG genotype is the major determinant of NMF, with disease severity as a secondary modifier. NMF components are reliably determined by a noninvasive and relatively inexpensive tape stripping technique.
Coronel Institute of Occupational Health, Academic Medical Center, Amsterdam, the Netherlands. s.kezic@amc.uva.nl
S
S
Kezic
G M
GM
O'Regan
N
N
Yau
A
A
Sandilands
H
H
Chen
L E
LE
Campbell
K
K
Kroboth
R
R
Watson
M
M
Rowland
W H Irwin
WH
McLean
A D
AD
Irvine
D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D000091344:Filaggrin Proteins; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007381:Intermediate Filament Proteins / Q000235:genetics* / Q000378:metabolism; D008297:Male; D009154:Mutation; D011761:Pyrrolidonecarboxylic Acid / Q000378:metabolism*; D012720:Severity of Illness Index; D012867:Skin / Q000378:metabolism*; D014560:Urocanic Acid / Q000378:metabolism*
C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D007381:Intermediate Filament Proteins; D014560:Urocanic Acid; D011761:Pyrrolidonecarboxylic Acid
J Invest Dermatol. 1994 Nov;103(5):731-41
7963664
J Invest Dermatol. 2008 May;128(5):1067-70
18408746
Br J Dermatol. 2009 Nov;161(5):1098-104
19857209
J Invest Dermatol. 1983 Aug;81(2):122-4
6135734
J Invest Dermatol. 2008 Aug;128(8):2117-9
18305568
J Cell Sci. 2009 May 1;122(Pt 9):1285-94
19386895
Br J Dermatol. 2000 Feb;142(2):288-97
10730763
J Invest Dermatol. 2009 Apr;129(4):1042-5
18987673
J Allergy Clin Immunol. 2010 Dec;126(6):1184-90.e3
21036388
J Invest Dermatol. 1967 Jan;48(1):11-7
6018239
Photochem Photobiol Sci. 2008 Jun;7(6):655-67
18528548
Br J Dermatol. 1994 Sep;131(3):383-96
7918015
Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):910-4
1371013
Dev Biol. 1986 May;115(1):84-92
3516761
J Allergy Clin Immunol. 2007 Jul;120(1):150-5
17512043
J Allergy Clin Immunol. 2010 Sep;126(3):574-80.e1
20621340
Nat Genet. 2007 May;39(5):650-4
17417636
Biochim Biophys Acta. 1982 Oct 28;719(1):110-7
7171620
Allergy. 2010 Jul;65(7):911-8
20132155
J Biol Chem. 1989 Jan 25;264(3):1837-45
2912987
J Biol Chem. 1992 Nov 25;267(33):23772-81
1429717
Biochemistry. 1990 Oct 9;29(40):9432-40
2248957
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1627-30
17234810